Technical Analysis for RDHL - Redhill Biopharma Ltd.

Grade Last Price % Change Price Change
grade C 7.8144 2.42% 0.18
RDHL closed up 2.42 percent on Friday, May 24, 2019, on approximately normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical RDHL trend table...

Date Alert Name Type % Chg
Slingshot Bearish Bearish Swing Setup 0.00%
Crossed Above 200 DMA Bullish 0.00%
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
MACD Bullish Signal Line Cross Bullish 2.42%
Stochastic Buy Signal Bullish 2.42%
Bollinger Band Squeeze Range Contraction 2.42%
Up 3 Days in a Row Strength 2.42%

Older signals for RDHL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.
Medicine Biopharmaceutical Autoimmune Diseases Antibiotics Inflammatory Bowel Disease Heart Failure Hypertension Gastroenterology Abdominal Pain Bacteria Crohn's Disease Nausea Vomiting Treatment Of Inflammatory Bowel Disease Treatment Of Hypertension Ventricular Dysfunction
Is RDHL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 11.49
52 Week Low 5.13
Average Volume 46,253
200-Day Moving Average 7.7608
50-Day Moving Average 8.2077
20-Day Moving Average 7.7197
10-Day Moving Average 7.6134
Average True Range 0.3026
ADX 20.67
+DI 17.1155
-DI 19.9221
Chandelier Exit (Long, 3 ATRs ) 7.392200000000001
Chandelier Exit (Short, 3 ATRs ) 8.3078
Upper Bollinger Band 8.0428
Lower Bollinger Band 7.3966
Percent B (%b) 0.65
BandWidth 8.370792
MACD Line -0.1475
MACD Signal Line -0.1715
MACD Histogram 0.024
Fundamentals Value
Market Cap 134.12 Million
Num Shares 17.2 Million
EPS -2.46
Price-to-Earnings (P/E) Ratio -3.18
Price-to-Sales 264.36
Price-to-Book 3.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.23
Resistance 3 (R3) 8.20 8.02 8.16
Resistance 2 (R2) 8.02 7.92 8.04 8.14
Resistance 1 (R1) 7.92 7.85 7.97 7.95 8.12
Pivot Point 7.74 7.74 7.77 7.76 7.74
Support 1 (S1) 7.64 7.64 7.69 7.67 7.51
Support 2 (S2) 7.46 7.57 7.48 7.49
Support 3 (S3) 7.36 7.46 7.46
Support 4 (S4) 7.39